Financing a cannabis cultivation facility acquisition

Financing a cannabis facility purchase is shaped less by the industry’s novelty at this point than by one structural fact: the asset that matters most — the licence — cannot be pledged or repossessed the way ordinary collateral can, so a lender’s whole structure has to work around that gap.

What’s actually lendable

Real property, growing and processing equipment, and inventory can be financed in a fairly conventional way. The licence itself is not a security interest a lender can enforce against on default, so underwriting leans more heavily on facility value and demonstrated cash flow than it would in a typical acquisition loan against a comparable industrial asset.

Why mainstream lenders are more cautious here

A federally licensed but plant-touching producer sits outside many lenders' standard risk appetite, which in practice means a narrower set of willing lenders, more conditions attached to the loan, and closer scrutiny of the single-wholesaler dependence than most acquisitions face. Working with a lender that has actually financed a licensed producer before, rather than a generalist commercial lender, tends to move the process faster.

The timing risk financing has to plan around

Because Health Canada’s review of new principals can take considerably longer than closing an ordinary purchase, a lender will typically want that clearance either completed or clearly on track before advancing the bulk of the funds. In practice, the licence-amendment timeline — not the appraisal — is usually the item that sets the pace of the financing.

Where a vendor take-back usually sits

A vendor take-back is a common way to bridge exactly that gap, letting the deal close economically while the buyer’s clearance and the licence amendment work their way through Health Canada, with the balance sized to be refinanced once the buyer is fully licensed and operating. Its terms and conditions precedent should be negotiated with that timeline explicitly in mind, not treated as a generic fallback.

Structuring around more than one funding source

Buyers combining a conventional lender with mezzanine or vendor financing should have the ranking and consent-to-security terms settled before the licence amendment is even filed, since renegotiating the financing structure mid-review adds delay on top of a process that is already slow by design.

What a lender will want to see

• Current licence status and canopy utilization relative to what is authorized.
• Wholesale contract terms and payment history with the provincial distributor.
• Facility compliance and inspection record, including anything tied to the current security standard.
• The buyer’s own clearance-application status and expected timeline.
• A realistic schedule for when the buyer expects to be fully licensed and operating.
• Confirmation of whether any proposed principal already holds Health Canada clearance on another facility.
• A capital stack that funds any genetics or intellectual property component through equity or vendor financing rather than assuming it is lendable collateral.

Why a lender treats an already-licensed buyer differently

A buyer who already holds a Health Canada licence on another facility, with principals already cleared, is often an easier credit to underwrite than a first-time entrant, because the lender can point to an actual operating and compliance track record rather than assessing a business plan and a set of individuals with no history in the sector. Lenders willing to finance licensed-producer acquisitions at all tend to price and structure the loan differently for this kind of buyer — sometimes advancing a larger share of funds before the licence amendment is fully cleared, on the strength of the buyer’s existing standing, where they would hold back with a first-time entrant until the clearance is confirmed.

Genetics and intellectual property generally aren’t lendable collateral

Proprietary strains and other cultivation intellectual property can be a real component of what the business is worth, but most lenders won’t extend credit against that value the way they would against a building or growing equipment, because there’s no established resale or enforcement mechanism if the loan defaults. In practice this means the intellectual property component of the purchase price is more often funded through equity, a vendor take-back, or general working capital than through a lender’s asset-based facility, and buyers should plan the capital stack accordingly rather than assuming a valuator’s genetics figure translates into financeable collateral.

Syndication and lender concentration in a narrow market

Because relatively few lenders are actively willing to finance licensed-producer acquisitions, larger facility purchases sometimes require syndicating the loan across more than one of those willing lenders rather than relying on a single institution, simply to reach the amount needed. That narrower lender pool is also why terms and appetite can vary more from one willing lender to the next than they would in a more conventional industry, and why it’s worth approaching more than one lender experienced in this specific sector before assuming any one quote reflects the market.

Funding the wait, not just the purchase

Because the facility generally can’t be operated under the buyer’s ownership until the licence amendment clears, some financing structures include a reserve or short-term facility specifically to cover interest and carrying costs during that gap, rather than assuming the deal’s regular cash flow will cover it from day one. Building that reserve into the financing request up front, rather than treating the clearance wait as a minor administrative delay, avoids a cash-flow gap opening up between closing and the day the buyer can actually generate revenue from the facility.